Updated April 15, 2014 Reducing the cost of new hepatitis C drugs Gilead Sciences reached a deal allowing Doctors Without Borders to procure the company's hepatitis C drug Sovaldi (sofosbuvir) at $900 for a 12-week treatment course, significantly below the price of $84 000 in the US, Bloomberg reported 4-11/Friday. Isabelle Meyer-Andrieux, an adviser at Doctors Without Borders, said the discounted price applies to countries including Kenya, Mozambique, Myanmar and India...... Doctors welcome hepatitis C drug rivals, Gilead still leads-"Competition will drive the price down, but probably not far enough," said Markus Peck-Radosavljevic, professor of medicine in the Medical University of Vienna and secretary-general of EASL.
Sovaldi/sofosbuvir Homepage Prescribing and patient information, financial assistance, research and news
Sovaldi is approved in HCV genotypes 1 and 4, treatment-naïve adults in combination with PEG-IFN and ribavirin and the first approved interferon-free treatment regimen for people with HCV genotypes 2 and 3. Overall cure rates are at 80%, response rates and treatment duration varies, depending on genotype, viral and host factors.
Sovaldi (Sofosbuvir) Homepage
OLYSIO/simeprevir homepage Prescribing and patient information, articles and important updates
Johnson & Johnson's protease inhibitor OLYSIO (Simeprevir) is approved for the treatment of HCV genotype 1, in combination with peginterferon alfa and ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non‑pegylated) with ribavirin.
Hepatitis C Clinical Trials - FDA Approved And Investigational Drugs
News, Research And Clinical Trials
See **Clinical Trials @ HCV Advocate For Enrollment Information
'Mix-and-match` approach to new hepatitis C drugs
The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals.
EASL is also encouraging European physicians to combine products from different pharmaceutical companies to achieve the most potent interferon-free regimens, often in advance of full phase III trial data, in its new hepatitis C treatment guidelines issued in April at the International Liver Congress in London.
Theseguidelines recommend that the first-generation protease inhibitors telaprevir or boceprevir should be used for treatment of genotype 1 infection only when newer options are not available. For other genotypes, the combination of pegylated interferon and ribavirin is described as `acceptable` where newer options are not available.
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ? After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas.
It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes.
The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
Copyright 2010 Design by DynamicWP. All rights reserved.